TD Cowen analyst Yaron Werber maintained a Hold rating on 2seventy bio (TSVT – Research Report) today. The company’s shares closed last Friday at $4.01.
Werber covers the Healthcare sector, focusing on stocks such as Argenx Se, 2seventy bio, and Ionis Pharmaceuticals. According to TipRanks, Werber has an average return of 20.8% and a 59.00% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for 2seventy bio with a $9.33 average price target.
See today’s best-performing stocks on TipRanks >>
Based on 2seventy bio’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $12.03 million and a GAAP net loss of $71.64 million. In comparison, last year the company earned a revenue of $13.41 million and had a GAAP net loss of $67.88 million
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TSVT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
2seventy bio (TSVT) Company Description:
2seventy bio Inc is primarely in the business of pharmaceutical preparations.
Read More on TSVT:
